ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE OF MENTAL HEALTH

Antidepressants and Intracellular Signaling Linked to BDNF

Active
Institution
VANDERBILT UNIVERSITY, TN
Principal investigator
Lisa M Monteggia
Funding
$532K
Duration
2005–2027
Open portfolio

Moonbase score

Still being scored

Abstract

Project Summary In the previous funding period we investigated the mechanism of rapid antidepressant activity of ketamine, an ionotropic glutamatergic n-methyl-d-aspartate (NMDA) receptor antagonist. We demonstrated that Brain- derived neurotrophic factor (BDNF), and its high affinity receptor TrkB, are required for the rapid antidepressant effects of ketamine as these effects are lost in forebrain specific BDNF knockout mice and conditional forebrain specific TrkB knockout mice. We found the antidepressant effects of ketamine require protein translation, but not transcription, resulting in increases in BDNF protein levels in the hippocampus that are critical for the behavioral effect. Ketamine's blockade of spontaneous NMDA receptor mediated neurotransmission inactivates eukaryotic elongation factor 2 kinase (eEF2K) resulting in dephosphorylation of its only known substrate, eukaryotic elongation factor 2, thereby increasing protein translation of target transcripts, including BDNF. In turn, BDNF is postulated to act via eliciting insertion of 3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) receptors at the postsynaptic membrane, which results in potentiation of AMPA receptor-mediated CA3-CA1 field excitatory postsynaptic potentials (fEPSPs) by ketamine. While this potentiation is suggested to be a cellular correlate of rapid antidepressant effects, its properties deviate from classical Hebbian forms of plasticity and rather coincide with homeostatic synaptic scaling seen after activity suppression. These data provide the basis for the novel hypothesis that BDNF-TrkB signaling regulates synaptic scaling in vivo that is critical for the rapid antidepressant effects of ketamine. The objective of this renewal is to specifically test the causal and instructive role of BDNF-TrkB signaling in the hippocampus in ketamine-mediated synaptic scaling and rapid antidepressant effects. Collectively, this information will provide novel information on the synaptic locus, as well as key molecules, necessary for ketamine's rapid antidepressant effects.

LOADING MOONBASE SCORE

NATIONAL INSTITUTE OF MENTAL HEALTHR01Molecular Neuropharmacology and Signaling Study Section[MNPS]potentiationantidepressantketamineprotein translationbdnfampanmdatrkb

Questions for VANDERBILT UNIVERSITY

Answered by the team behind this research.

Same researchers, same institution, same topic, scored first.